What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?
What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?
Pfizer highlighted several factors affecting its 2024 EPS that won't carry over to 2025.Pfizer Inc. (NYSE:PFE) will conduct an investor call on Tuesday to provide full-year 2025 financial guidance.
辉瑞公司（纽交所：PFE）将在周二召开投资者电话会议，提供2025财年的全面财务指导。
Ahead of the call, Goldman Sachs has outlined its expectations for the guide and commentary on the upcoming year.
在电话会议之前，高盛已概述了其对指导意见和即将到来的年度的预期。
The analyst anticipates that Pfizer's management will guide to EPS in the mid-to-high $2 range with core business growth offset by the $0.30 in favorable but non-recurring items during 2024.
分析师预计辉瑞管理层将指导每股收益在2美元中高区间，而核心业务增长将被2024年0.30美元的有利但非经常性项目所抵消。
Pfizer highlighted several factors affecting its 2024 EPS that won't carry over to 2025.
辉瑞强调了几个影响其2024年每股收益的因素，这些因素不会延续到2025年。
The 2024 EPS includes one-time boosts: a $1.2 billion benefit from Paxlovid stockpiling and a U.S. government true-up and equity income from its stake in Haleon Plc (NYSE:HLN). However, Haleon income will not appear in 2025, as Pfizer's ownership in Haleon is dropping below 20%.
2024年的每股收益包括一次性提升：来自Paxlovid库存积累的12亿美金收益以及美国政府的补偿和其在Haleon Plc（纽交所：HLN）股份的权益收入。然而，Haleon的收入在2025年将不会出现，因为辉瑞在Haleon的持股比例已降至20%以下。
Goldman forecasts for 2025 revenues of $64.9 billion and EPS of $3.13, which compares to consensus estimates of $63.2 billion and $2.89, respectively.
高盛预测2025年收入为649亿美金，每股收益为3.13美元，而共识预期为632亿美金和2.89美元。
Goldman Sachs notes that the impact of the IRA Part D redesign will likely be addressed in the company's 2025 guidance. However, the analyst does not expect the details to be broken down by individual products but instead based on the overall commercial portfolio.
高盛指出，IRA Part D重组的影响可能将在公司2025年的指导中得到解决。然而，分析师不希望细节按单个产品进行区分，而是基于整体商业组合。
The analyst expects Paxlovid sales of $4.3 billion vs. consensus of $3.7 billion, though slightly more conservative on Vyndaqel sales of $5.9 billion vs. consensus of $6.2 billion.
分析师预计Paxlovid的销售额为43亿美金，而共识为37亿美金，尽管对Vyndaqel的销售额略为保守，预计为59亿美金，而共识为62亿美金。
Year-to-date, Eliquis has performed well, showing 12% growth thanks to market expansion and increased market share. This growth has been supported by Pfizer's commercial team and boosted by Part D catastrophic coverage in 2024.
截至目前，阿哌沙班表现良好，因市场扩张和市场份额增加而增长12%。这一增长得益于辉瑞的商业团队，并受到2024年D类药物灾难性覆盖的推动。
Looking ahead to 2025, Pfizer expects continued growth opportunities driven by market expansion and the potential for further share gains.
展望2025年，辉瑞预计将持续获得由市场扩张和进一步市场份额增长潜力驱动的增长机会。
"We highlight dynamics across key topics and frame potential points of discussion with potential read-across beyond Pfizer specifically, noting that they are the only large cap pharma company in our coverage that we expect to opine on 2025 ahead of the new year," Goldman analyst writes.
“我们强调关键话题的动态，并框定潜在讨论的切入点，指出辉瑞特定之外的潜在延伸，并注意到它是我们覆盖的唯一一家我们预计将在新年前对2025年发表意见的大盘制药公司，”高盛的分析师写道。
Price Action: PFE stock is down 0.39% at $25.48 at last check Monday.
价格动态：截至周一最后检查，辉瑞股票下跌0.39%，报25.48美元。
- Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent
- Ozempic制造商诺和诺德投资超过10亿在新的丹麦生产设施，计划从Catalent再增加3个。
Photo via Shutterstock.
图片来自shutterstock。
